Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed alongside t ...

AstraZeneca has begun the worldwide withdrawal of its COVID vaccine - ending an era in which it saved millions of lives while being dogged by controversy.The jab, developed at Oxford University, was once hailed as "the vaccine for the world" because it could be stored in fridges rather than the ultra-cold freezer temperatures originally required for alternative mRNA shots, making it more suitable for developing countries. But AstraZeneca (AZ) said demand for the jab had tailed off as more up-to-date vaccine ...

In this photo illustration a covid-19 vaccine is seen with the AstraZeneca logo in the background. (Photo Illustration by Nikos Pekiaridis/NurPhoto via Getty Images)Pharmaceutical giant AstraZeneca on Wednesday said it planned to withdraw its Covid-19 vaccine as demand for it has declined. The so-called Vaxzevria vaccine was developed with the University of Oxford and was one of the first shots against Covid-19 to hit the market during the coronavirus pandemic, with millions of people around the world recei ...

The pharmaceutical giant AstraZeneca said on Tuesday it is withdrawing its COVID-19 vaccine worldwide citing low demand and a "surplus of available updated vaccines" since the pandemic. The vaccine — called Vaxzevria – was one of a number of shots released onto the market by pharmaceutical companies aimed at preventing people from catching COVID-19. The company said it would proceed to withdraw Vaxzevria's marketing authorizations within Europe. The vaccine was never approved in the U.S. by the FDA. POLAND ...

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by it ...

Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS) a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that, following clearance from the French Ministry of Economy and satisfaction of all other closing conditions, AstraZeneca (NASDAQ:AZN) completed the additional equity investm ...

ToplineThe Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like Novo Nordisk’s diabetes drug Ozempic by making it harder to produce generic drugs.The “bogus” patent listings keep brand name drug prices “artificially high,” regulators said.NurPhoto via Getty Images Key FactsThe FTC sent warning letters to 10 pharmaceutical companies—including Novo Nordisk, AstraZeneca, Gl ...

A dad who suffered a brain injury just days after receiving a British-developed COVID vaccine has told Sky News he would never have had the jab if he had known of the risk of rare but serious side effects.Jamie Scott, who has two young boys and is now unable to work, is suing AstraZeneca for what he says is damage caused by the jab in April 2021. He alleges the pharmaceutical giant exaggerated the vaccine's effectiveness and downplayed its risks.AstraZeneca denies the claims made against them.In his first T ...

AstraZeneca’s (AZN) first-quarter 2024 core earnings of $1.03 per American depositary share (ADS) beat the Zacks Consensus Estimate of 95 cents. Core earnings of $2.06 per share rose 7% year over year on a reported basis and 13% at constant exchange rates (“CER”).Total revenues of $12.68 billion rose 17% on a reported basis and 19% at CER, driven by rising product sales and continued growth in Alliance revenues from partnered medicines. Revenues also beat the Zacks Consensus Estimate of $11.92 billion.All g ...

Key TakeawaysAstraZeneca's sales of cancer drugs helped the pharmaceutical firm beat first-quarter estimates for earnings and revenue.Sales of oncology treatments rose 23%, and those for medicines made with partners jumped 59%.American depositary receipts (ADRs) of AstraZeneca traded near their all-time high on the news. American depositary receipts (ADRs) of AstraZeneca (AZN) traded near their all-time high as the Anglo-Swedish pharmaceutical company had solid first-quarter demand for its cancer drugs. Ast ...